# CSL Limited - Raw Research Archive

**Date:** 2025-12-04
**Query:** "CSL Limited AI strategy and digital transformation 2024-2025"
**Sources:** 60 citations
**Method:** Perplexity MCP Research

---

## Key Citations (Verified URLs)

### Tier 1 - Official Sources
1. https://investors.csl.com/pdf/56bf77f4-8eff-40ff-bb67-c890e3a3476e/CSL-FY25-Results-and-Major-Strategic-Initiatives.pdf
2. https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf
3. https://investors.csl.com/impactreport/2025/
4. https://www.csl.com/-/media/csl/documents/csl-governance-docs/corporate-governance-statement-2025.pdf
5. https://investors.csl.com/annualreport/2025/
6. https://www.csl.com/we-are-csl/our-leadership/mark-hill

### Tier 2 - Executive/Partner Sources
7. https://aws.amazon.com/solutions/case-studies/csl-agenticai/
8. https://www.coriniumintelligence.com/content/how-is-csl-using-data-and-ai-to-innovate-and-improve-outcomes
9. https://www.csl.com/we-are-csl/vita-original-stories/2020/artificial-intelligence-at-csl
10. https://www.csl.com/we-are-csl/vita-original-stories/2022/innovative-new-tech-coming-to-us-csl-plasma-centers
11. https://newsroom.csl.com/2025-10-29-Australian-scientists-awarded-2-5-million-CSL-Centenary-Fellowships-to-advance-lifelong-immunity-research-and-AI-designed-proteins

### Tier 3 - Media/Industry Sources
12. https://www.cbinsights.com/research/ai-readiness-index-pharma-2025/
13. https://www.imd.org/future-readiness-indicator/home/pharmaceuticals-2024/
14. https://www.aha.org/aha-center-health-innovation-market-scan/2025-10-21-how-ai-transforming-clinical-trials
15. https://www.csl.com/we-are-csl/vita-original-stories/2024/every-cure-gets-48-million-for-ai-powered-rare-disease-research
16. https://www.pharmaceutical-technology.com/news/csl-to-pump-1-5bn-into-us-plasma-supply-chain/
17. https://www.csl.com/we-are-csl/our-leadership/paul-mckenzie-glg
18. https://www.klover.ai/csl-ai-strategy-analysis-of-dominance-in-biotechnology-biopharma-ai/

---

## Key Metrics Extracted

| Metric | Value | Source |
|--------|-------|--------|
| Wave Planning Acceleration | 10x | AWS Case Study |
| Application Discovery | 12x faster | AWS Case Study |
| Overall Discovery | 20x improvement | AWS Case Study |
| Operational Cost Savings | 30% | AWS Case Study |
| Data Centers to Exit | 17 | AWS Case Study |
| Data Migration | 17,500 TB | AWS Case Study |
| VMware Servers | 5,000+ | AWS Case Study |
| Data Centers Total | 29 | AWS Case Study |
| Clinical Trials | 59 active | Impact Report |
| R&D Expenses | $1.359B (17% of revenue) | Annual Report |
| Target Cost Savings | >$500M/year by FY28 | FY25 Results |
| Restructuring Costs | $700-770M | FY25 Results |
| US Investment | $1.5B over 5 years | Pharmaceutical Technology |
| Rika Machines Deployed | 200+ | Impact Report |
| Plasma Centers | 300+ | Impact Report |
| Employees | 32-33,000 | Annual Report |

---

## Key Quotes

**CEO Paul McKenzie:**
> "We took a step back and decided how we wanted to reinvent CSL. Our goal was to create a robust environment that fosters innovation while keeping things simple, cost-effective, and productive."

**CDIO Mark Hill:**
> "We set out to build a technology foundation that's agile and resilient—one that makes it easier for our people to do their best work and make CSL an even better place to work focusing on efficiency."

**Milica Ng, Senior Director Data Science:**
> "Data science supports the drug development pipeline right throughout. Starting with research and pre-clinical development where we look at target discovery and also validation where we look at drug selection and optimization and also understanding the disease understanding the path mechanisms of disease at the molecular level."

**John Thompson, Global Head AA&AI:**
> "CSL is taking a two-pronged approach that includes a Center of Excellence and a Community of Practices on advanced analytics and AI. Data scientists are part of both groups and working on numerous projects throughout CSL."

---

## Research Reuse Notes

- Digital Core: AWS Transform for VMware with agentic AI
- 10x Acceleration: Wave planning from 1 month to days
- Deviation AI: Production deployment for clinical trial monitoring
- Rika System: Plasma donation 90-120 min → 60-80 min
- Center of Excellence + Community of Practices: Dual AI structure
- EU AI Act: Proactive compliance for high-risk AI
- Not Top 5 AI Readiness: Gap vs Eli Lilly, Roche, Novo Nordisk

---

## Competitive Context

| Pharma Company | AI Readiness Rank | Key Strength |
|----------------|-------------------|--------------|
| Eli Lilly | #1 | 13 AI investments since Aug 2023 |
| Merck KGaA | #2 | 10 investments, 22 partnerships |
| Bayer | #3 | 21 strategic AI relationships |
| CSL | Not Top 5 | Strong infrastructure, governance |

---

## Surprise Finding

**AWS Agentic AI Deployment:**
- CSL is using true agentic AI (autonomous AI agents) for infrastructure
- 4.6M records analyzed for wave planning
- Amazon Q Business for natural language infrastructure queries
- This is more advanced than many larger pharma companies

**Governance Strength:**
- EU AI Act proactive compliance
- Corporate Governance Statement 2025
- "Careful and thoughtful approach" to clinical AI
- Human oversight maintained despite ML outperforming clinicians

---

*Raw research archived for reuse*
*Next refresh: After cloud migration completion (Dec 2025) or FY26 results*
